Joseph Pearlberg - Infinity Pharmaceuticals Insider

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.43  0.11  4.33%

Vice President - Clinical Development

Dr. Joseph Pearlberg, M.D. Ph.D., serves as Vice President Clinical Development of the Company
  President Since 2017  Ph.D    
Joseph Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. During his career, he also held various medical and research positions at Dana Farber Cancer Center and Massachusetts General Hospital. Additionally, Dr. Pearlberg was a Genentech Research Fellow from 1997 to 1999. He earned a M.D. from University of California, San Francisco, a Ph.D. in molecular biology from Harvard University and a B.A. from University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of (24.62) % which means that it has lost $24.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.26) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 12.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Infinity Pharmaceuticals Inc has Current Ratio of 4.93 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records


Stephanie HallerDimension Therapeutics Inc
Yael CohenVascular Biogenics Ltd
Athena KartsaklisVBI Vaccines Inc
Eyal BreitbartVascular Biogenics Ltd
Adam BuckleyVBI Vaccines Inc
Erez FeigeVascular Biogenics Ltd

Entity Summary

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 22 people.Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 22 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Analyst Recommendations Now

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
Hide  View All  NextLaunch Analyst Recommendations

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Infinity Pharmaceuticals Inc to your portfolio

Top Management

Infinity Pharmaceuticals Leadership Team
Joseph Pearlberg, President, Ph.D
Melissa Hackel, President, MBA
William Bertrand, President
Vito Palombella, EVP
Jeffrey Berkowitz, Director
Lawrence Bloch, President, MBA
Norman Selby, Director, MBA
Jose Baselga, Director, Ph.D
Michael Venuti, Director, Ph.D
Michael Kauffman, Director
Eric Lander, Director, Ph.D
David Beier, Director
Julian Adams, President
Anthony Evnin, Director, Ph.D
Gwendolyn Fyfe, Director
Sujay Kango, President, MBA
Ian Smith, Director
Adelene Perkins, Chairman, MBA

Stock Performance

Infinity Pharmaceuticals Performance Indicators